Why the study?
Does oral encainide reduce the frequency of ventricular arrhythmias in patients with chronic high-frequency ventricular arrhythmias or NSVT?
Population
28 patients
Design
Cohort
Follow-up
36 months
Authors
Loading...
May aid arrhythmia suppression in observational cohorts; leaves open randomized confirmation of net clinical benefit.
Does oral encainide reduce the frequency of ventricular arrhythmias in patients with chronic high-frequency ventricular arrhythmias or NSVT?
Oral encainide effectively reduces the frequency of PVCs and NSVT without impairing left ventricular function, though severe proarrhythmic effects (sustained VT) may occur in patients with marked LV impairment.
Bongiorni et al. (1988) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: